author-photo

Peter M. Ferguson

University of Sydney
Royal Prince Alfred Hospital

33

Papers

300

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Analysis of clinical and molecular profiles of patients with innate resistance to ANTI-PD-1 +/- ANTI-CTLA-4 immunotherapy in metastatic melanoma

2021 Pathology
Show All
- Source
- Cite
- Save
Citations (0)
γδ T cells in Merkel cell carcinomas have a proinflammatory profile prognostic of patient survival.

2021 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (1)
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.

2021 Pathology
Show All
- Source
- Cite
- Save
Citations (14)
Transplant-associated penile Kaposi sarcoma managed with single agent paclitaxel chemotherapy: a case report

2021 BMC Urology
Show All
- Source
- Cite
- Save
Citations (1)
Biomarkers in cutaneous melanoma: castles in the sky and useful developments

2021 Pathology
- Peter M. Ferguson
Show All
- Source
- Cite
- Save
Citations (0)
Diagnostic accuracy of pigmented labial macules by in vivo reflectance confocal microscopy and correlation among techniques

2020 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (2)
Publisher Correction: Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

2020 Nature Reviews Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas.

2020 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (2)
A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)